Brief: Helix Biopharma Q1 loss per share C$0.04

Helix Biopharma

14/12/2016 24:46

Dec 13 (Reuters) - Helix Biopharma Corp  HBP.TO  
    * Helix Biopharma Corp- Considers securing additional funds, 
expected to be through issuance of equity securities of company, 
to be of utmost importance 
    * Helix Biopharma - Cash reserves as at Oct 31, 2016, are 
insufficient to see current research and development initiatives 
through to completion. 
    * Helix Biopharma Corp. announces fiscal first quarter 2017 
results 
    * Q1 loss per share C$0.04 
 
    Source text for Eikon:  ID:nCCN81ns6v  
    Further company coverage:  HBP.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))